Global Polymyositis Treatment Market, By Treatment (Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal antibodies), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Polymyositis Treatment Market Analysis and Size
The polymyositis treatment market is expected to witness significant growth during the forecast period. Increasing cases of chronic muscle inflammation boost the polymyositis treatment market. People with a family history of muscular dystrophy and the existence of certain nerve diseases that affect muscles also boost up the growth of polymyositis treatment. The ongoing pandemic is significantly changing the pharma and healthcare sector dynamics.
Data Bridge Market Research analyses a growth rate in the polymyositis treatment market in the forecast period 2022-2029. The expected CAGR of polymyositis treatment market is tend to be around 3% in the mentioned forecast period. The market was valued at USD 100 million in 2022, and it would grow upto USD 126.68 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Polymyositis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal antibodies), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Bausch Health Companies Inc. (Canada), Accord Healthcare (U.K.), Genentech, Inc (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Merz Pharma (Germany), Akorn, Incorporated (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Polymyositis is an uncommon, rare, autoimmune disease that affects the body's muscles and weakens them. The disease inflames muscles and other related body tissue such as blood vessels. There is no permanent cure for the disease, but a treatment may decrease the symptoms. It usually affects adults post 30 years of age.
Global Polymyositis Treatment Market Dynamics
Drivers
- Increase in Autoimmune Disorders
According to the National Institute of Environmental Health Sciences, more than 80 autoimmune diseases have been identified namely diabetes (type 1), multiple sclerosis, muscular dystrophy, rheumatoid arthritis, lupus, and celiac disease. An increase in the occurrence of these diseases drives the global polymyositis treatment market. This boosts the growth of the market.
- Rising Demand for Oral Drugs
Oral drugs is projected to boost the market growth. Oral form of drugs are very much feasible and becomes very convenient for patients. Majority of the products are available in capsule form and tablet form and it is a very viable route of administration.
Opportunities
- Rise in Elderly Population
Several studies have shown that elderly population is more prone to suffer from this disease. As per the Aging World reports from 2015, there were around 562 million people 65 and older worldwide, which increased the disease's incidence and fuelled the growth of the polymyositis treatment market.
- Increasing Demand for Retail Pharmacies
The rise in the number of polymyositis therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in established countries create opportunities for the market growth. Furthermore, patients favour retail pharmacies for purchasing drugs, as these are easily available.
Restraints/Challenges
- Limited Studies and Surveys
There are very few studies and surveys that is impeding the growth of the market. Only a nominal amount of data are available concerning the studies. A few studies are mainly focused on groups from a single hospital wherein only a limited patients are witnessed. Thus, this hampers the growth of the market.
- High Cost
The huge expenditure that is associated with polymyositis treatment medications hamper the market growth. This disease involves treatment with corticosteroids, different immunosuppressive agents which demands huge expenditure. This acts as a major hindrance for the market.
This polymyositis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the polymyositis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Polymyositis Treatment Market
COVID-19 has left a major global public health crisis that has impacted practically every business. Its long-term consequences are expected to influence industry growth during the forecast period. It has been witnessed that COVID-19 can induce a systemic inflammatory response, and its clinical appearances are different. It has been stated that COVID-19 patients may develop myositis and interstitial pulmonary disease similar to polymyositis treatment.
In the post-pandemic era, the market is projected to rise because of the availability of diverse treatment options such as anti-inflammatory therapy may be beneficial to patients. Other than that, physical therapy, heat therapy are also helpful.
Global Polymyositis Treatment Market Scope
The polymyositis treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Immunosuppressant
- Immunoglobulins
- Corticosteroids
- Alkylating agents
- Monoclonal antibodies
Route of Administration
- Oral
- Topical
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Polymyositis Treatment Market Regional Analysis/Insights
The polymyositis treatment market is analyzed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the polymyositis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been observing a positive growth for polymyositis treatment market during the forecast period due to increased healthcare and R&D expenditure and the presence of skilled professionals.
Asia-Pacific dominates the market due to increased inflammatory diseases, increased awareness for joint disorders through advertisement and media, and rapidly improving health care infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Polymyositis Treatment Market Share Analysis
The polymyositis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to polymyositis treatment market
Key players operating in the polymyositis treatment market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Bausch Health Companies Inc. (Canada)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Bausch Health Companies Inc. (U.S.)
- Accord Healthcare (U.K.)
- Genentech, Inc (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Merz Pharma (Germany)
- Akorn, Incorporated (U.S.)
SKU-